Here is the short version. The sections below explain why each point matters.
- Take everything else, tablets, supplements and food, at least 30 minutes after your oral Wegovy dose, every day.
- If you take levothyroxine, tell whoever prescribes it that you are starting oral Wegovy, and expect a thyroid blood test within the next few weeks.
- If you take insulin or a sulfonylurea for diabetes, tell whoever manages that medicine before you start.
- If you take a blood-thinning medicine such as warfarin, tell your regular prescriber.
- Omeprazole and similar acid-suppressing medicines do not need any special change.
- Always tell every prescriber and pharmacist about everything you take, including anything you have just started or stopped.
The 30-minute window problem is local and mechanical. Any other tablet, capsule or supplement taken within 30 minutes of your dose competes for the same small, concentrated pocket of stomach fluid that SNAC needs to work in. In studies, taking oral semaglutide alongside several other oral medicines cut its own exposure by around 34%, with peak concentration down by about 32%. The fix is timing: everything else waits until at least 30 minutes after the semaglutide tablet, not the other way round.
The systemic problem is different, and timing does not fix it. Semaglutide slows gastric emptying as a whole-body effect of the medicine circulating in your blood, all day, every day, regardless of when you took your morning tablet. This changes how some other oral medicines, taken hours later, are absorbed. Spacing your doses further apart does not remove this effect. Only monitoring does.
If you take levothyroxine for an underactive thyroid, tell whoever prescribes it that you are starting oral Wegovy, and expect a thyroid blood test a few weeks in and again after significant weight loss. That single instruction covers three separate issues that often get muddled together.
First, levothyroxine is one of the other tablets covered by the 30-minute rule. Taken too close to your oral Wegovy dose, it reduces your semaglutide absorption, not the other way round.
Second, semaglutide raises total thyroxine exposure by around 33% through its whole-body slowing of gut transit. Spacing the two tablets further apart does not change this, because the effect is not about timing at all.
Third, as you lose weight over the following months, the levothyroxine dose you need is likely to fall, because dosing is broadly based on lean body mass. In one bariatric-surgery cohort, roughly half of patients needed a lower levothyroxine dose after significant weight loss.
The second and third issues point the same way: towards having too much thyroid hormone in circulation over time. Left unchecked, that can contribute to an irregular heart rhythm and reduced bone density. That is why the blood tests matter, and why any change to the dose itself is a decision for whoever prescribes your levothyroxine, not something to adjust yourself.
- A racing or irregular heartbeat, tremor, unusual sweating, poor sleep or new anxiety. Mention these to whoever manages your thyroid medicine
Two practical timing options handle the first issue. Take the oral Wegovy tablet first, wait the full 30 minutes, then take levothyroxine, with as long a further gap before breakfast as you can manage. Or move levothyroxine to bedtime, at least three hours after your last food: trial evidence shows this works at least as well as the morning slot for most people.
Any tablet or capsule, prescribed or over the counter, needs to wait until at least 30 minutes after your oral Wegovy dose. This includes calcium and iron supplements, multivitamins, blood pressure tablets, statins and everyday painkillers.
Calcium, iron and levothyroxine also have their own long-standing separation rule from each other, of around four hours. So if you are reorganising your morning around oral Wegovy, it is a good moment to check your full supplement routine is not clashing on multiple fronts at once.
These and oral Wegovy can be taken together with no dose adjustment needed. A randomised study giving omeprazole 40 mg alongside oral semaglutide found only a small, statistically non-significant increase in semaglutide exposure.
The question comes up because SNAC works by raising stomach acidity locally, so it is reasonable to wonder whether a medicine that suppresses acid across the whole stomach would interfere with it. The trial data say it does not. The usual 30-minute separation from other tablets still applies as routine practice, but not because of any acid-suppression concern specifically.
Tell whoever manages your diabetes medicine if you are starting oral Wegovy, because your insulin or sulfonylurea dose may need adjusting alongside it.
Oral Wegovy is not licensed for diabetes; that is a different tablet. But some people taking it for weight management also have diabetes managed separately. Here the concern is not absorption: combining two blood-sugar-lowering effects raises the risk of hypoglycaemia, or low blood sugar, which can cause shakiness, sweating and confusion.
Tell your regular prescriber if you take a medicine with a narrow safety margin, such as warfarin, so they can consider closer monitoring, for example more frequent INR checks, if appropriate.
This is a precaution rather than a known problem. Delayed gastric emptying can change how quickly other oral medicines, taken well after your morning dose, are absorbed later in the day. For most medicines this makes no practical difference, but a narrow safety margin leaves less room for that shift to matter.
This is worth clearing up directly: the contraceptive-switching caution you may have read about does not apply to oral Wegovy.
Orforglipron, a different, non-peptide oral GLP-1 medicine, carries a specific caution about switching from an oral contraceptive to a non-oral method, because of how it is metabolised. That caution is specific to orforglipron. Oral Wegovy, which is semaglutide, works through a different pathway and does not carry that warning. Do not assume a rule for one oral GLP-1 medicine automatically applies to another.
Oral Wegovy is not yet dispensed in Spain. EU-wide authorisation was granted on 15 July 2026, but Spain still needs its own product information and a pricing notification before pharmacies can stock it, a process that historically has taken well over a year: the injectable version of the same medicine took about 28 months from EU authorisation to reaching Spanish pharmacies.
No confirmed date exists as of late August 2026. Once available, the same interaction profile described here, drawn from the EU-wide product information and published trial data, will apply in Spain. Check the AEMPS CIMA medicines database for the current authorised status of any product.
We review and continue medicines you already take while you are in Spain, through an asynchronous clinical review by a Spanish-registered English-speaking doctor.
- Prescribing or supplying oral Wegovy, which is not available in Spain
- Starting any weight-management medicine for the first time
- Adjusting your levothyroxine, insulin or warfarin dose in response to a GLP-1 medicine
- Arranging or interpreting thyroid or INR blood tests
As a new weight-management start it sits outside our continuation-only remit in any case, and a dedicated GLP-1 service such as Nivelta, our sister service, also from Doctor Abbs SL, is the right route for that decision. If you are already on a different regular medicine and want to check whether it needs a doctor's input while you are here, start a clinical review.